U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT06908031) titled 'SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer' on April 01.
Brief Summary: To explore the efficacy and safety of short-course radiotherapy combined with mFOLFOX6, PD-1 monoclonal antibody and cetuximab (for RAS/BRAF Wild-Type)/bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma through a prospective study, providing high-level evidence-based medical evidence for the use in the treatment of high-risk rectal cancer.
Study Start Date: April 02
Study Type: INTERVENTIONAL
Condition:
Rectal Adenocarcinoma
High-Risk Cancer
MSS
Intervention:
RADIATION: Short-Course Ra...